FAIRFIELD, N.J., Feb. 16 /PRNewswire-FirstCall/ -- Bradley
Pharmaceuticals, Inc. (NYSE: BDY) today announced that Daniel Glassman,
President and CEO, will participate in the Roth Capital Partners 19th
Annual OC Conference at the Ritz Carlton, Laguna Niguel, CA. Mr. Glassman
is scheduled to present on Wednesday, February 21, 2007, from 3:00 to 3:30
PM (EST) 12:00 to 12:30 PM (PST).
The presentation will be webcast live and can be accessed by visiting
http://www.bradpharm.com and clicking on Calendar of Events or by clicking on
http://www.wsw.com/webcast/roth9/bdy/ .
It is recommended that listeners log on 15 minutes early in order to
register. For those unable to participate during the live webcast, an
archive version of the presentation will be available for 90 days beginning
5 PM (EST) on February 21, 2007.
Please visit Bradley Pharmaceuticals web site at: http://www.bradpharm.com.
Bradley Pharmaceuticals common stock is listed on the NYSE under the
symbol BDY.
Bradley Pharmaceuticals, Inc. was founded in 1985 as a specialty
pharmaceutical company and markets to niche physician specialties in the
U.S. and 38 international markets. Bradley's success is based upon its core
strengths in marketing and sales which enables the company to Commercialize
brands that fill unmet patient and physician needs; Develop new products
through life cycle management; and In-License phase II and phase III drugs
with long-term intellectual property protection that upon approval leverage
Bradley's marketing and sales expertise to increase shareholder value.
Bradley Pharmaceuticals is comprised of Doak Dermatologics, specializing in
therapies for dermatology and podiatry; Kenwood Therapeutics, providing
gastroenterology, OBGYN, respiratory and other internal medicine brands;
and A. Aarons, which markets authorized generic versions of Doak and
Kenwood therapies.
Important announcement:
Bradley Pharmaceuticals will present at the Raymond James & Associates
28th Annual Institutional Investors Conference, at 11 AM at the Hyatt
Regency Grand Cypress in Orlando, FL, March 5, 2007.
Bradley Pharmaceuticals will present at the Banc of America Securities
Health Care Conference 2007, to be held at The Four Seasons Hotel in Las
Vegas, Nevada, May 30 through June 1, 2007.
Safe Harbor for Forward-Looking Statements
This release contains "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements that address activities, events or
developments that Bradley expects, believes or anticipates will or may
occur in the future, such as sales and earnings estimates, other
predictions of financial performance, market acceptance of Bradley's
products and the achievement of initiatives to enhance corporate governance
and long-term shareholder value. Forward-looking statements are based on
Bradley's experience and perception of current conditions, trends, expected
future developments and other factors it believes are appropriate under the
circumstances and are subject to numerous risks and uncertainties, many of
which are beyond Bradley's control. These risks and uncertainties include
Bradley's ability to: successfully acquire, develop, integrate or sell new
products, estimate sales; favorably resolve the pending SEC informal
inquiry; remediate its material weaknesses in its internal controls; or
effectively react to other risks and uncertainties described from time to
time in Bradley's SEC filings. Further, Bradley cannot accurately predict
the impact on its business of the approval, introduction, or expansion by
competitors of generic or therapeutically equivalent or comparable versions
of Bradley's products or of any other competing products. Bradley
undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise.
SOURCE Bradley Pharmaceuticals, Inc.
 back to top
Related links:
http://www.bradpharm.com
http://www.wsw.com/webcast/roth9/bdy/
CONTACT:
Anthony Griffo, Investor Relations of Bradley
Pharmaceuticals, Inc., +1-973-882-1505, ext. 313
|
